General Information of Drug (ID: DMXE6ML)

Drug Name
FX-007 Drug Info
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Preclinical [1]
Cross-matching ID
TTD Drug ID
DMXE6ML

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Entrectinib DMMPTLH Non-small-cell lung cancer 2C25 Approved [3]
Repotrectinib DM9FB2T Non-small-cell lung cancer 2C25 Approved [4]
Larotrectinib DM26CQR Solid tumour/cancer 2A00-2F9Z Approved [5]
MIM-D3 DMZHN5B Alzheimer disease 8A20 Phase 3 [6]
SNA-120 DMPN314 Plaque psoriasis EA90.0 Phase 2 [7]
CT 327 DMQXL1T Plaque psoriasis EA90.0 Phase 2 [8]
ONO-7579 DMXLPYE Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
Altiratinib DMUJCBT Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
PLX7486 DM0IVGU Pancreatic cancer 2C10 Phase 1 [10]
DS-6051 DM0RD4F Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tropomyosin-related kinase A (TrkA) TTTDVOJ NTRK1_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037108)
2 Preclinical trail of FX007 for treating osteoarthritis. Flexion Therapeutics Inc.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
6 Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8.
9 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
10 National Cancer Institute Drug Dictionary (drug id 747694).
11 National Cancer Institute Drug Dictionary (drug id 766123).